作者
Sophie Drapier, Anne-Sophie Gillioz, Emmanuelle Leray, Julie Péron, Tiphaine Rouaud, Annaig Marchand, Marc Vérin
发表日期
2012/1/1
期刊
Parkinsonism & related disorders
卷号
18
期号
1
页码范围
40-44
出版商
Elsevier
简介
BACKGROUND
The efficacy of continuous subcutaneous apomorphine infusion (APO) has been evaluated in advanced Parkinson’s disease in several open-label studies but never in a population of patients for whom subthalamic nucleus deep brain stimulation (STN-DBS) was contraindicated.
METHODS
The aim of this study was to evaluate the efficacy and cognitive safety of APO at 12-month follow-up in 23 advanced parkinsonian patients (mean age: 62.3 years; mean disease duration: 13.9 years) whose dopa-resistant axial motor symptoms and/or cognitive decline constituted contraindications for STN-DBS. Their motor and cognitive status were evaluated before APO and 12 months afterwards.
RESULTS
After one year, patients expressed high levels of satisfaction, with a mean rating on the Visual Analog Scale of 52.8% under APO. Daily OFF time, recorded in a 24-h diary, was reduced by 36% and ON time …
学术搜索中的文章
Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications
S Drapier, AS Gillioz, E Leray, J Péron, T Rouaud… - Parkinsonism & related disorders, 2012